Top-News

Genprex Aktie News

Aktie
WKN:  A41L3N ISIN:  US3724463027 US-Symbol:  GNPX Branche:  Biotechnologie Land:  USA
3,36 $
+0,01 $
+0,30%
2,8857 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
4,76 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Genprex News

28.04.25 - PR Newswire
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma PR Newswire
24.04.25 - PR Newswire
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting PR Newswire
22.04.25 - PR Newswire
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings PR Newswire
26.03.25 - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting PR Newswire
25.03.25 - PR Newswire
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions PR Newswire
04.03.25 - PR Newswire
Genprex to Participate at BIO Europe Spring 2025
Genprex to Participate at BIO Europe Spring 2025 PR Newswire
19.02.25 - PR Newswire
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System PR Newswire
18.02.25 - PR Newswire
Genprex Provides Update on Diabetes Gene Therapy Program
Genprex Provides Update on Diabetes Gene Therapy Program PR Newswire
13.02.25 - PR Newswire
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer PR Newswire
23.01.25 - PR Newswire
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell ...
06.01.25 - PR Newswire
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
16.12.24 - PR Newswire
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »